Clinical Trial Update: Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL) [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial evaluating Ublituximab and Umbralisib with CHOP followed by U2 maintenance in newly diagnosed mantle cell lymphoma was terminated with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Ublituximab (ublituximab)
• umbralisib

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Mantle Cell Lymphoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-09-28